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ESMO Minimum Clinical Recommendations for diagnosis,
adjuvant treatment and follow-up of primary breast cancer
Incidence
. The crude incidence of breast cancer in the European Union
is 109.9/100 000 females per year, the mortality 38.4/100 000
females per year, however with marked geographical
variation.
Diagnosis
. The diagnosis is based on clinical palpation, bilateral mam-
mography and ultrasound. Pathologic diagnosis with fine
needle aspiration or core needle biopsy should be obtained
prior to any surgical procedure. Final pathological diagnosis
should be made according to the World Health Organisation
classification and the TNM (2002) staging system analyzing
all tissue removed.
Staging and risk assessment
. TNM-staging based on H&E staining, standardized grading,
description of histologic type, and of resection margins
should be reported. Determination of estrogen receptor (ER)
and progesterone receptor (PR) status is mandatory, prefer-
ably by immunohistochemistry [III, B]. Reports of immuno-
histochemical results for ER and PR should include the
percentage of ER- and PR-positive cells. When available,
immunohistochemical determination of HER2 receptor
expression should be performed at the same time. When
semi-quantitative results of immunohistochemistry are
ambiguous ( + + ), in situ hybridization (FISH or CISH) to
determine HER2 gene amplification should be considered.
. Routine staging examinations include physical examination,
full blood counts, routine chemistry including liver
enzymes, alkaline phosphatase, calcium; assessment of
menopausal status.
. In patients with higher risk (N2 with >_4 pos. axillary nodes,
or T4 tumors, or with laboratory signs or clinical signs or
symptoms suspicious for the presence of metastases), chest
X-ray, abdominal ultrasound and isotopic bone scan are
appropriate [III, B].
. Explore the possibility of hereditary cancer and evaluate
adequate counselling of relatives [IV, D]. For node negative
patients the following risk stratification to guide adjuvant
treatment is recommended [III, B]. Even tumors smaller
than 1 cm can benefit from adjuvant treatment with che-
motherapy and/or tamoxifen [II, B]. See Table 1.
Treatment plan
. Multidisciplinary treatment planning should be used to inte-
grate local and systemic therapies as well as their sequence
[III, B].
Local therapy
Invasive carcinoma
. Generally, operable breast cancer is initially treated by sur-
gery, using breast conserving surgery or mastectomy, both
in combination with axillary dissection. Contraindications to
breast-conserving surgery include multicentric tumors, large
tumors (larger than 3–4 cm), tumor-involved margins after
resection. The technique of sentinel lymph node biopsy may
be used in centers with documented experience and accu-
racy. Breast radiotherapy is strongly recommended after
breast conserving surgery [I, A]. Post-mastectomy radiother-
apy has been recommended for patients with four or more
positive axillary nodes [II, B] and is suggested for T3
tumors with positive axillary nodes [III, B].
Ductal carcinoma in situ (DCIS)
. When DCIS is treated by breast conserving surgery, all sub-
groups of patients benefit from adjuvant radiation as well as
from adjuvant tamoxifen [I, B]. Adjuvant tamoxifen for
DCIS reduces the recurrence rate of in situ and of invasive
breast cancer.
Primary systemic therapy
. Primary systemic therapy is indicated for inoperable locally
advanced breast cancer (stage IIIB: T4, N2-3, regional M1)
[III, B]. If possible it should be followed by both surgery
and radiotherapy and postoperative systemic treatment.
Primary systemic therapy is an alternative for large
operable breast cancer, to allow breast conserving surgery
[I, A].
Adjuvant systemic therapy
. Before deciding whether to use adjuvant systemic therapy,
the prognosis without adjuvant therapy should be estimated.
For each individual, the choice of adjuvant therapy must
take into account the potential benefits, possible side effects,
and patient preference.
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Tamoxifen
. Patients with ER and/or PR positive tumors should receive
tamoxifen 20mg/d for 5 years [I, A]. Patients with ER and
PR negative tumors [I, A] and/or HER2-positive tumors [II,
C] should not receive it. Tamoxifen should be started when
chemotherapy is completed [II, A]. Concurrent use of
tamoxifen with radiation therapy is not recommended due
to potentially increased risk of lung toxicity [III, C].
Aromatase inhibitors
. The use of aromatase inhibitors in stead of or in sequence
with tamoxifen significantly reduces the risk of recurrence
compared with tamoxifen, but no survival benefit has been
demonstrated so far [I, A]. Furthermore, the absolute differ-
ence in recurrence-free survival is <5%. The long-term car-
diovascular and skeletal adverse effects associated with
aromatase inhibitors are an issue of concern. Certain sub-
groups (ER-positive/PR-negative, HER2-positive) seem to
have a more marked benefit by the use of an aromatase
inhibitor [III, C].
Ovarian ablation
. Ablation of ovarian function is an alternative to CMF-based
regimens for premenopausal patients with endocrine respon-
sive tumors [I, A]. Bilateral ovarectomy and irradiation of
the ovaries lead to irreversible ablation of ovarian function.
LHRH analogs generally lead to reversible ovarian suppres-
sion. They should be given for at least 2 years [III, D].
Chemotherapy
. Adjuvant chemotherapy should use a combination regimen,
as shown in Table 2 [I, A]. In node-positive and node-
negative disease anthracycline-containing therapy has been
shown to be slightly superior in efficacy to intravenous
CMF [I, A]. However, there seems to be a threshold dose
for adjuvant anthracyclines, below which efficacy becomes
inferior [I, A]. 4 cycles of AC have been shown to be com-
parable in efficacy to 6 cycles of CMF [I, A]. At the St Gal-
len consensus conference 2003 4 cycles of AC or 6 cycles
of CMF were considered adequate treatment for ER and/or
PR positive patients, while ER and PR negative tumors were
considered candidates for more prolonged chemotherapy.
Adding 4 cycles of paclitaxel to 4 cycles of AC improves
outcome in node-positive patients [I, A]. It is possible that
other more intensive anthracycline- and/or taxane containing
regimens are equally effective. Encouraging results have
been described with dose-dense therapy using hematopoietic
growth factors in addition to AC and taxanes. This approach
is not considered standard at the present time.
Follow-up
. History taking, eliciting of symptoms and physical examin-
ation every 3–6 months for 3 years, every 6–12 months for
3 years, then annually [A], with attention paid to long-term
side effects, e.g. osteoporosis.
. Ipsilateral (after breast conserving surgery) and contralateral
mammography every 1–2 years [D].
. Not routinely recommended for asymptomatic patients:
blood counts, chemistry, chest X-ray, bone scan, liver ultra-
sound, CT-scans of chest and abdomen, and any tumor mar-
kers such as CA 15–3 or CEA [I, A].
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
Table 1.
Tumor sizeER/PRa GradingAgeb Comment
Low risk <2 cm positive 1 >_35 All factors
must be present
Higher risk >_2 cm negative 2–3 <35 At least one
factor present
aUsing immunohistochemistry, ER/PR is usually considered positive,
when >_10% of cells are positive (weakly or strongly) for either ER or PR
[IV, B]. Some endocrine responsiveness seems to remain even when only
1–10% of tumor cells are ER weakly positive [III, B]. ER and/or PR
positive patients are considered “endocrine responsive”.
bNo exact age threshold has been defined.
Table 2.
Node Negative (N0) Patient
Low risk, endocrine
responsive
Tamoxifen
OR
Nil
Higher risk, endocrine responsive:
- Premenopausal Chemotherapy, ovarian
ablation ! tamoxifen
OR
Chemotherapy ! tamoxifen
OR
Ovarian ablation
- Postmenopausal Tamoxifen*
OR
Chemotherapy ! tamoxifen
Higher risk, endocrine non-responsive:
- Premenopausal Chemotherapy
- Postmenopausal Chemotherapy
Node Positive (N1) Patient
Endocrine responsive:
- Premenopausal Chemotherapy! tamoxifen
± ovarian ablation
- Postmenopausal Chemotherapy! tamoxifen*
OR
Tamoxifen*
Endocrine non-responsive:
- Premenopausal Chemotherapy
- Postmenopausal Chemotherapy
*In postmenopausal patients, aromatase inhibitors (anastrozole, letrozole,
exemestane) are an alternative.
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are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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